SEARCH

SEARCH BY CITATION

References

  • 1
    Gao M, Nettles RE, Belema M, Snyder LB, Nguyen VN, Fridell RA, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010;465:96-100.
  • 2
    McPhee F, Sheaffer AK, Friborg J, Hernandez D, Falk P, Zhai G, et al. Preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032). Antimicrob Agents Chemother 2012;56:5387-5396.
  • 3
    Pol S, Ghalib RH, Rustgi VK, Martorell C, Everson GT, Tatum HA, et al. Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial. Lancet Infect Dis 2012;12:671-677.
  • 4
    Pol S, Ghalib R, Rustgi V, Martorell C, Everson GT, Tatum HA, et al. High rates of SVR24 for BMS-790052, a NS5A replication complex inhibitor, in combination with peg-IFNa-2a and ribavirin (RBV): phase 2a trial in treatment-naïve HCV-genotype 1 subjects. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, 2011; Oral Abstract H1-376.
  • 5
    Bronowicki JP, Pol S, Thuluvath PJ, Larrey D, Martorell CT, Rustgi VK, et al. 1195 BMS-650032, an NS3 inhibitor, in combination with peginterferon alpha-2a and ribavirin in treatment-naive subjects with genotype 1 chronic hepatitis c infection. J Hepatol 2011;54(Suppl 1:)S472.
  • 6
    Bronowicki JP, Pol S, Thuluvath P, Larrey D, Martorell CT, Rustgi VK, et al. 1096 Asunaprevir (ASV; BMS-650032), an NS3 protease inhibitor, in combination with peginterferon and ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C infection. J Hepatol 2012;56(Suppl 2):S431-S432.
  • 7
    Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, Ghalib R, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012;366:216-224.
  • 8
    Sheaffer AK, Lee MS, Hernandez D, Chaniewski S, Yu F, Falk P, et al. Development of a chimeric replicon system for phenotypic analysis of NS3 protease sequences from HCV clinical isolates. Antivir Ther 2011;16:705-718.
  • 9
    Fridell RA, Wang C, Sun JH, O'Boyle DR 2nd, Nower P, Valera L, et al. Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations. Hepatology 2011;54:1924-1935.
  • 10
    Pasquinelli C, McPhee F, Eley T, Villegas C, Sandy K, Sheridan P, et al. Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C. Antimicrob Agents Chemother 2012;56:1838-1844.
  • 11
    Fridell RA, Qiu D, Wang C, Valera L, Gao M. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob Agents Chemother 2010;54:3641-3650.
  • 12
    McPhee F, Friborg J, Levine S, Chen C, Falk P, Yu F, et al. Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir. Antimicrob Agents Chemother 2012;56:3670-3681.
  • 13
    Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1207-1217.
  • 14
    Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364:2417-2428.
  • 15
    Chayama K, Takahashi S, Toyota J, Karino Y, Ikeda K, Ishikawa H, et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology 2012:55:742-748.
  • 16
    Suzuki Y, Ikeda K, Suzuki F, Toyota J, Karino Y, Chayama K, et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol 2013 [Epub ahead of print].
  • 17
    Sun J-H, O'Boyle DR 2nd, Zhang Y, Wang C, Nower P, Valera L, et al. Impact of a baseline polymorphism on the emergence of resistance to the hepatitis C virus nonstructural protein 5A replication complex inhibitor, BMS-790052. Hepatology 2012;55:1692-1699.
  • 18
    Lenz O, Fevery B, Vijgen L, Verbeeck J, Peeters M, Beumont-Mauviel M, et al. 9 TMC435 in patients infected with HCV genotype 1 who have failed previous pegylated interferon/ribavirin treatment: virologic analyses of the ASPIRE trial. J Hepatol 2012;56(Suppl 2):S5.
  • 19
    Manns MP, Gane E, Rodriguez-Torres M, Stoehr A, Yeh C-T, Marcellin P, et al. Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C: A randomized phase II study. Hepatology 2012;56:884-893.
  • 20
    Cheng G, Peng B, Corsa A, Yu M, Nash M, Lee YJ, et al. 1172 Antiviral activity and resistance profile of the novel HCV NS5a inhibitor GS-5885. J Hepatol 2012;56:S464.
  • 21
    Wong KA, Worth A, Brainard DM, Lawitz E, Miller MD, Mo H. 1215 Persistence of NS5A GS-5885 drug resistance mutations following 3 days of monotherapy in genotype-1 HCV patients is dependent on the HCV subtype and specific mutation. J Hepatol 2012;56:S482.
  • 22
    Foy E, Li K, Wang C, Sumpter R Jr, Ikeda M, Lemon SM, et al. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 2003;300:1145-1148.
  • 23
    Karino Y, Toyota J, Ikeda K, Suzuki F, Chayama K, Kawakami Y, et al. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct acting antivirals daclatasvir and asunaprevir. J Hepatol 2013 [Epub ahead of print].
  • 24
    Meyerhans A, Vartanian JP, Wain-Hobson S. DNA recombination during PCR. Nucleic Acids Res 1990;18:1687-1691.